Terns Pharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Terns Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q3 2024.
  • Terns Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$21.9M, a 26.3% increase year-over-year.
  • Terns Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$88.1M, a 3.6% decline year-over-year.
  • Terns Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$90.2M, a 49.5% decline from 2022.
  • Terns Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$60.3M, a 20.3% decline from 2021.
  • Terns Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$50.2M, a 25.2% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$88.1M -$21.9M +$7.82M +26.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$95.9M -$22.7M -$4.84M -27% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$91.1M -$22.4M -$845K -3.93% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$90.2M -$21M -$5.2M -32.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 -$85M -$29.8M -$12.9M -77% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$72.1M -$17.9M -$3.97M -28.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$68.1M -$21.5M -$7.76M -56.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$60.3M -$15.8M -$1.57M -11% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$58.8M -$16.8M -$4.99M -42.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$53.8M -$13.9M -$3.19M -29.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$50.6M -$13.8M -$436K -3.27% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-14
Q4 2021 -$50.2M -$14.2M -$4.32M -43.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 -$45.8M -$11.8M -$400K -3.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$45.4M -$10.7M -$1.05M -10.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$44.4M -$13.3M -$4.34M -48.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$40.1M -$9.93M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-07
Q3 2020 -$11.4M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$9.69M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-15
Q1 2020 -$9M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.